Escitalopram for older adults with generalized anxiety disorder: A randomized controlled trial

JAMA

Volumn 301, Issue 3, 2009, Pages 295-303

  Lenze, Eric J ^a   Rollman, Bruce L ^b   Shear, M Katherine ^c   Dew, Mary Amanda ^b   Pollock, Bruce G ^d   Ciliberti, Caroline ^b   Costantino, Michelle ^b   Snyder, Sara ^b   Shi, Peichang ^a   Spitznagel, Edward ^a   Andreescu, Carmen ^b   Butters, Meryl A ^b   Reynolds III, Charles F ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; ESCITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR; CITALOPRAM;

ADULT; AGED; ANXIETY; ARTICLE; BACTERIAL ENDOCARDITIS; BRADYCARDIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SENESCENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL STATUS; SOMNOLENCE; SWEATING; TREATMENT RESPONSE; TREMOR; UNITED STATES; URINARY DYSFUNCTION; ANXIETY DISORDER; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

AGED; AGED, 80 AND OVER; ANXIETY DISORDERS; CITALOPRAM; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 58749117239     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.977     Document Type: Article

References (55)

1. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272(22):1741-1748.
2. Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(suppl 8):24-34.
3. Hoffman DL, Dukes EM, Wittchen H-U. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72-90.
4. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):19-39.
5. Kessler RC, Berglund PA, Dewit DJ, Ustün TB, Wang PS, Wïttchen HU. Distinguishing generalized anxiety disorder from major depression: prevalence and impairment from current pure and comorbid disorders in the US and Ontario. Int J Methods Psychiatr Res. 2002;11(3):99-111.
6. Beekman AT, Bremmer MA, van Balkom AJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study, Amsterdam. Int J Geriatr Psychiatry. 1998;13(10):717-726.
7. Tolin DF, Robison JT, Gaztambide S, Blank K. Anxiety disorders in older Puerto Rican primary care patients. Am J Geriatr Psychiatry. 2005;13(2):150-156.
8. Ettner SL, Hermann RC. Provider specialty choice among Medicare beneficiaries treated for psychiatric disorders. Health Care Financ Rev. 1997;18(3):43-59.
9. Wetherell JL, Thorp SR, Patterson TL, Golshan S, Jeste DV, Gatz M. Quality of life in geriatric generalized anxiety disorder: a preliminary investigation. J Psychiatr Res. 2004;38(3):305-312.
10. Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol. 2003;71(2):309-319.
11. Diefenbach GJ, Hopko DR, Feigon S, et al. "Minor GAD": characteristics of subsyndromal GAD in older adults. Behav Res Ther. 2003;41(4):481-487.
12. Mantella RC, Butters MA, Dew MA, et al. Cognitive impairment in late-life generalized anxiety disorder. Am J Geriatr Psychiatry. 2007;15(8):673-679.
13. Caudle DD, Senior AC, Wetherell JL, et al. Cognitive errors, symptom severity, and response to cognitive behavior therapy in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2007;15(8):680-689.
14. Kessler RC, Ormel J, Demler O, Stang PE. Comorbid mental disorders account for the role impairment of commonly occurring chronic physical disorders: results from the National Comorbidity Survey. J Occup Environ Med. 2003;45(12):1257-1266.
15. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry. 2008;30(3):208-225.
16. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr. 2004;9(10):716-723.
17. Koepke HH, Gold RL, Linden ME, Lion JR, Rickels K. Multicenter controlled study of oxazepam in anxious elderly outpatients. Psychosomatics. 1982;23(6):641-645.
18. Benítez CI, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatr Psychiatry. 2008;16(1):5-13.
19. Herings RMC, Stricker BHC, deBoer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801-1807.
20. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther. 1998;64(6):684-692.
21. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278(1):27-31.
22. Allgulander C, Bandelow B, Hollander E, et al; World Council of Anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003;8(8)(suppl 1):53-61.
23. Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146-150.
24. Schuurmans J, Comijs H, Emmelkamp PM, et al. A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2006;14(3):255-263.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
27. Rollman BL, Fischer GS, Zhu F, Belnap BH. Comparison of electronic physician prompts versus waitroom case-finding on clinical trial enrollment. J Gen Intern Med. 2008;23(4):447-450.
28. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: Administration Booklet. Washington, DC: American Psychiatric Press; 1996.
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
30. Folstein MF, Folstein SE, McHugh PR. "Minimental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
31. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237-248.
32. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rev ed. Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976.
33. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-495.
34. Jette AM, Haley SM, Coster WJ, et al. Late life function and disability instrument, I: development and evaluation of the disability component. J Gerontol A Biol Sci Med Sci. 2002;57(4):M209-M216.
35. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Medical Outcomes Trust; 1993.
36. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inf J. 1991;25:411-424.
37. Whyte EM, Dew MA, Gildengers A, et al. Time course of response to antidepressants in late-life major depression: therapeutic implications. Drugs Aging. 2004;21(8):531-554.
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Inc; 1988.
39. Beck JG, Stanley MA, Zebb BJ. Characteristics of generalized anxiety disorder in older adults: a descriptive study. Behav Res Ther. 1996;34(3):225-234.
40. Chen YH, Liu GH. Testing for crossover of two hazard functions using Gail and Simon's method. J Biopharm Stat. 2006;16(3):313-326.
41. Katz IR, Reynolds CF III, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002;50(1):18-25.
42. Davidson J, Allgulander C, Pollack MH, et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008;23(6):519-526.
43. Steffens DC, McQuoid DR. Impact of symptoms of generalized anxiety disorder on the course of late-life depression. Am J Geriatr Psychiatry. 2005;13(1):40-47.
44. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007;190:344-349.
45. Endicott J, Russell JM, Raskin J, et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry. 2007;68(4):518-524.
46. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864-872.
47. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005;87(2-3):161-167.
48. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16(1):14-20.
49. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999;20(3):277-287.
50. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006;51(14):923-929.
51. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004;164(3):327-332.
52. Richards JB, Papaioannou A, Adachi JD, et al; Canadian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194.
53. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65(7):795-803.
54. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006;163(5):813-821.
55. Pollock BG. Geriatric psychiatry: psychopharmacology: general principles. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry/VIII. Baltimore, MD: Williams & Wilkins; 2005:3716-3720.